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http://dx.doi.org/10.1016/j.ccr.2013.10.022SUMMARYGlucocorticoid resistance is a major driver of therapeutic failure in T cell acute lymphoblastic leukemia
(T-ALL). Here, we identify the AKT1 kinase as amajor negative regulator of the NR3C1 glucocorticoid receptor
protein activity driving glucocorticoid resistance in T-ALL. Mechanistically, AKT1 impairs glucocorticoid-
induced gene expression by direct phosphorylation of NR3C1 at position S134 and blocking gluco-
corticoid-induced NR3C1 translocation to the nucleus. Moreover, we demonstrate that loss of PTEN and
consequent AKT1 activation can effectively block glucocorticoid-induced apoptosis and induce resistance
to glucocorticoid therapy. Conversely, pharmacologic inhibition of AKT with MK2206 effectively restores
glucocorticoid-induced NR3C1 translocation to the nucleus, increases the response of T-ALL cells to gluco-
corticoid therapy, and effectively reverses glucocorticoid resistance in vitro and in vivo.Significance
Improving the outcomes of patients with acute lymphoblastic leukemia (ALL) will require the identification of specific
molecular mechanisms driving resistance to therapy and developing new pharmacologic strategies to neutralize them.
Primary resistance to glucocorticoids, defined as failure to achieve robust cytoreduction after a week of glucocorticoid
therapy, is of particular importance as it is associated with very poor prognosis. Here, we show that AKT1 can drive
resistance to glucocorticoids via direct inhibition of the glucocorticoid receptor. Consistently, pharmacologic inhibition
of AKT effectively reverses glucocorticoid resistance. These results highlight the potential role of AKT1 as therapeutic
target in the treatment of glucocorticoid-resistant T cell ALL.
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AKT Inhibition Reverses Glucocorticoid ResistanceINTRODUCTION
Glucocorticoids are small lipophilic compounds derived from
cortisol, a natural adrenal hormone that signals via the glucocor-
ticoid receptor alpha, a nuclear receptor ligand-activated tran-
scription factor encoded by the NR3C1 gene (Schlossmacher
et al., 2011). Glucocorticoids play a fundamental role in the
treatment of all lymphoid tumors because of their capacity to
induce apoptosis in lymphoid progenitor cells (Inaba and Pui,
2010; Pui et al., 2011, 2012). The importance of glucocorticoid
therapy in lymphoid malignancies is underscored by the strong
association of primary glucocorticoid resistance with poor
prognosis in childhood acute lymphoblastic leukemia (ALL).
Thus, prednisone poor response, defined as failure to show
effective cytoreduction after 7 days of glucocorticoid therapy,
is strongly associated with increased risk of relapse and thera-
peutic failure (Do¨rdelmann et al., 1999; Inaba and Pui, 2010),
and in vitro resistance to glucocorticoids is associated with
unfavorable prognosis in this disease (Hongo et al., 1997; Inaba
and Pui, 2010; Klumper et al., 1995).
Primary glucocorticoid resistance is particularly frequent in
T cell ALL (T-ALL) (Hongo et al., 1997; Inaba and Pui, 2010;
Klumper et al., 1995), leading us to hypothesize that activation
of one or more oncogenic signaling pathways implicated in
T cell transformation could be driving primary glucocorticoid
resistance in T-ALL directly by interfering with glucocorticoid
receptor function or indirectly via inhibition of glucocorticoid-
induced apoptosis. In this context, AKT1 emerged as a plausible
candidate as PI3K-AKT activation plays a major role in the
pathogenesis of T-ALL, particularly in leukemias harboring
mutations and deletions in the PTEN tumor suppressor gene
(Palomero et al., 2007). Moreover, in silico analysis of signaling
factors modulating transcriptional signatures associated with
glucocorticoid resistance in T-ALL pointed to a potential role of
AKT1 as driver of glucocorticoid resistance in T-ALL. These
results, together with the association of mutational loss of
PTEN and increased AKT1 phosphorylation with primary
glucocorticoid resistance in the clinic (Bandapalli et al., 2013;
Morishita et al., 2012) and the availability of PI3K-AKT specific
inhibitors in clinical trials for the treatment of human cancer,
prompted us to analyze the mechanistic role of AKT1 in the
control of glucocorticoid resistance in T-ALL.
RESULTS
AKT1 Binds to the NR3C1 Glucocorticoid
Receptor Protein
Activation of gene expression by glucocorticoids is a multistep
process that requires effective release of the glucocorticoid
receptor from heat shock protein complexes, translocation to
the nucleus, and formation of a multiprotein transcriptional
complex on the promoter of glucocorticoid target genes
(Heitzer et al., 2007). To test if AKT1 can interact with and
inhibit the glucocorticoid receptor protein, we transfected
293T cells with plasmid constructs driving the expression of
Flag-tagged AKT1 and hemagglutinin (HA)-tagged NR3C1 and
isolated glucocorticoid receptor-containing protein complexes
via immunoprecipitation using an anti-HA antibody. Western
blot analysis demonstrated the presence of Flag-AKT1 inCaHA-NR3C1 immunoprecipitates, suggesting that AKT1 can
interact with NR3C1 in vivo (Figure 1A). Reciprocal immuno-
precipitation experiments confirmed the association between
Flag-AKT1 and HA-NR3C1 (Figure 1B). Moreover, immuno-
precipitation of NR3C1 protein complexes from the T-ALL cell
lines DND41 and CCRF-CEM demonstrated that endogenous
NR3C1 and AKT1 can interact in T-ALL lymphoblast cells (Fig-
ure 1C and Figure S1A available online). In addition, immunoflu-
orescence analysis showed colocalization of NR3C1 and AKT1
in DND41 and CCRF-CEM cells (Figures 1D and S1B). Finally,
glutathione S-transferase (GST)-pulldown assays showed that
recombinant GST-NR3C1 fusion protein can directly interact
with His-tagged AKT1 in vitro (Figure 1E).
AKT1 Phosphorylates S134 in the NR3C1 Protein
AKT1 kinase substrates are typically phosphorylated by AKT at
RXRXXS/T motifs (Mok et al., 1999; Ozes et al., 1999; Zimmer-
mann and Moelling, 1999). Phospho-AKT motif scanning anal-
ysis of NR3C1 revealed a potential AKT phosphorylation motif
131RSTS134 (Figures 1F and S1C), suggesting that the gluco-
corticoid receptor could be an AKT1 substrate phosphorylated
at serine 134. To test this possibility, we expressed HA-tagged
wild-type NR3C1 (HA-NR3C1) or an HA-tagged form of the
glucocorticoid receptor with a serine-to-alanine substitution
at position 134 (HA-NR3C1 S134A) in cells infected with retro-
viruses expressing MYR-AKT1. Protein immunoprecipitation of
NR3C1 with an antibody against HA and subsequent western
blot analysis with an antibody recognizing the phospho-RXXS/
T AKT phosphorylation motif showed the presence of an HA-
NR3C1 phospho-AKT band in cells expressing the wild-type
glucocorticoid receptor, but not in cells expressing the HA-
NR3C1 S134A mutant (Figure 1G). Consistently, in vitro kinase
assays in which we analyzed the capacity of the AKT1 kinase
to phosphorylate the wild-type or S134A glucocorticoid
receptor proteins demonstrated that AKT1 can effectively
phosphorylate recombinant wild-type NR3C1 protein in vitro,
but not the serine 134 to alanine NR3C1 mutant protein (Fig-
ure 1H). Mass spectrometry analysis of HA-NR3C1 protein
isolated from MYR-AKT1-expressing cells demonstrated the
presence of serine phosphorylation at position 134 of the gluco-
corticoid receptor (Figures 1I and 1J), which was effectively
abrogated (control S134P:non-P = 0.47; MK2206 S134P:non-
P = 0.03; Table S1) upon treatment with MK2206, a highly potent
and selective inhibitor of AKT (Hirai et al., 2010). Finally, andmost
notably, western blot analysis with the AKT phosphorylation
motif antibody showed decreased AKT phosphorylated NR3C1
in NR3C1 immunoprecipitates from CCRF-CEM T-ALL cells
upon AKT inhibition with MK2206 (Figure 1K).
AKT Signaling Inhibits NR3C1 Nuclear Translocation
following Glucocorticoid Treatment
After establishing the interaction and phosphorylation of the
glucocorticoid receptor by AKT1, we sought to elucidate the
relevance of the NR3C1 S134 phosphorylation for glucocorticoid
receptor function. Glucocorticoid-induced cytoplasmic-nuclear
shuttling is strictly required for glucocorticoid receptor activity,
which functions as a ligand-activated transcription factor
(Heitzer et al., 2007). U2OS cells, which express undetectable
levels of endogenous NR3C1 (Figure S2A), showed cytoplasmicncer Cell 24, 766–776, December 9, 2013 ª2013 Elsevier Inc. 767
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Figure 1. AKT1 Interacts with the Gluco-
corticoid Receptor Protein and Regulates
NR3C1 S134 Phosphorylation
(A) Western blot analysis of AKT1 and activated
AKT1 after NR3C1 immunoprecipitation in 293T
cells expressing Flag-tagged AKT1 and HA-tag-
ged NR3C1.
(B) NR3C1 western blot analysis after AKT1
immunoprecipitation in 293T cells expressing
Flag-tagged AKT1 and HA-tagged NR3C1.
(C) Western blot analysis of AKT1 after NR3C1 pro-
tein immunoprecipitation in DND-41 T-ALL cells.
(D) Immunofluorescence colocalization analysis
of AKT (green) and NR3C1 (red) proteins in
DND41 cells. Cell nuclei stained with TO-PRO3
are shown in blue. Scale bar, 10 mm.
(E) Analysis of AKT1-NR3C1 interaction via west-
ern blot analysis of protein complexes recovered
after NR3C1-GST pulldown of recombinant His-
tagged AKT1.
(F) Partial alignment of the glucocorticoid receptor
protein sequences flanking S134.
(G) Western blot analysis of NR3C1 phospho-
rylation using an antibody against the AKT phos-
pho-motif in NR3C1 protein immunoprecipitates
from U2OS cells expressing MYR-AKT1 together
with HA-NR3C1 or HA-NR3C1 S134A.
(H) In vitro kinase analysis of AKT1 phospho-
rylation of recombinant NR3C1 (GST-NR3C1) and
NR3C1 S134A mutant (GST-NR3C1 S134A) pro-
teins. The top shows P-32 autoradiography after
SDS-PAGE, and corresponding protein loading is
shown at the bottom.
(I) Electrospray ionization MS/MS spectrum of
monophosphorylated peptide STpS134VPENPK
(S132 to K140) obtained after trypsin digestion of
NR3C1 isolated from cells expressing constitu-
tively active AKT1. TOF, time-of-flight.
(J) Collision-induced dissociation of the molecular
ion, [M+2H]2+ at a mass-to-charge ratio (m/z) of
519.72 (mass=1,037.42Da)corresponding toS134.
Characteristic b- and y-fragment ions—including
y7, which contains pSer and features the loss of
98 Da (elimination of phosphoric acid)—are shown.
(K) Western blot analysis of NR3C1 phosphoryla-
tion using an anti AKT phospho-motif antibody in
NR3C1 immunoprecipitates from CCRF-CEM
cells expressing HA-NR3C1 treated with vehicle or
the MK2206 AKT inhibitor.
See also Figure S1 and Table S1.
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AKT Inhibition Reverses Glucocorticoid Resistancelocalization of retrovirally expressed HA-tagged glucocorticoid
receptor protein, which was completely relocalized to the
nucleus upon dexamethasone treatment (Figure 2A). Notably,
expression of MYR-AKT1 in these cells resulted in impaired nu-
clear relocalization of NR3C1 after dexamethasone treatment
(Figure 2B). In addition, and in contrast with wild-type glucocor-
ticoid receptor, the NR3C1 S134A mutant protein showed
increased nuclear localization in basal conditions and effective
nuclear relocalization upon dexamethasone treatment (Fig-
ure 2C), even upon expression of MYR-AKT1 (Figure 2D). Next,
we analyzed the capacity of the MK2206 AKT inhibitor to
modulate glucocorticoid-induced translocation of NR3C1 to
the nucleus in T-ALL cells. CCRF-CEM and MOLT3, two PTEN
null, glucocorticoid-resistant T-ALL cell lines expressing high768 Cancer Cell 24, 766–776, December 9, 2013 ª2013 Elsevier Inc.levels of AKT activation, showed cytoplasmic localization of
NR3C1 in basal conditions, which was only partially relocalized
to the nucleus upon dexamethasone treatment (Figures 2E and
S2B). Inhibition of AKT with MK2206 effectively enhanced
glucocorticoid-induced translocation of the NR3C1 protein to
the nucleus in these cells (Figures 2E and S2). Notably, similar
results were obtained in primograft T-ALL lymphoblasts in which
inhibition of AKT with MK2206 increased the nuclear transloca-
tion of the NR3C1 protein following glucocorticoid treatment
(Figure 2F).
Transcriptionally, MYR-AKT1 impaired the capacity of
NR3C1 to activate a luciferase reporter construct under the
control of a synthetic glucocorticoid response element (Fig-
ure 3A). Consistently, AKT activation via MYR-AKT1 expression
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Figure 2. AKT1-Mediated S134 Phosphorylation of the NRC3C1 Protein Impairs Dexamethasone-Induced Glucocorticoid Receptor
Nuclear Translocation
(A–D) Confocal microscopy analysis and quantitation of the distribution of NR3C1 cellular localization in U2OS cells expressing HA-NRC31 (A), HA-NRC31 and
MYR-AKT1 (B), HA-NRC31 S134A (C), or HA-NRC31 S134A and MYR-AKT1 (D) in basal conditions (DMSO) and after dexamethasone (Dexa; 1 mM) stimulation.
Scale bars, 20 mm.
(E) Cellular localization analysis of NR3C1 via nuclear and cytoplasmic cell fractionation and analysis of AKT1 signaling in cell lysates from CCRF-CEM T-ALL
cells treated with vehicle only (DMSO), dexamethasone (Dexa; 1 mM), the MK2206 AKT inhibitor (1 mM), or MK2206 plus dexamethasone (1 mM each).
(F) Cellular localization analysis of NR3C1 via western blot analysis of nuclear and cytoplasmic cell fractions in cell lysates from primograft T-ALL lymphoblasts.
Tubulin and MAX proteins are shown as controls for cytosolic and nuclear fractions. C, cytoplasmic fraction; N, nuclear fraction. Data in (A) through (D) are
represented as mean ± SD.
See also Figure S2.
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Figure 3. AKT Activation Inhibits Glucocorticoid-Induced Gene
Expression
(A) Luciferase reporter analysis of dexamethasone-induced glucocorticoid
receptor transactivation in U2OS cells expressing MYR-AKT1 compared with
GFP-only-expressing controls using a synthetic glucocorticoid response
element reporter.
(B) Western blot analysis of PTEN expression and AKT activation in DND41 T-
ALL cells infected with lentiviruses expressing a PTEN shRNA construct
(shRNA PTEN) or a control shRNA targeting theRenilla luciferase gene (shRNA
LUC).
(C) Real-time PCR analysis of glucocorticoid-regulated transcripts in control
and PTEN knockdown DND41 cells treated with vehicle (DMSO) only or 1 mM
dexamethasone (Dexa).
(D) Heat map representation of the top differentially expressed genes between
control DND41 cells treated with vehicle only (Control) versus 1 mM dexa-
methasone (Dexa) and corresponding transcript levels in control and dexa-
methasone-treated PTEN knockdown cells. The scale bar shows color-coded
differential expression, with red indicating higher levels and blue indicating
lower levels of expression.
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impaired key effector responses mediating glucocorticoid-
induced cell death, including glucocorticoid receptor auto-
upregulation (Geng et al., 2008) and induction of BCL2L11,
a proapototic factor essential for glucocorticoid-induced cell
death (Wang et al., 2003) (Figures 3B and 3C; Figures S3A and
S3B). Consistently, glucorticoid-induced apoptosis was signifi-
cantly blunted in DND41 and KOPTK1 MYR-AKT-expressing
cells compared with controls (Figure S3C). To better analyze
the potential impact of mutational loss of PTEN in T-ALL on the
global transcriptional program induced by glucocorticoids, we
performed microarray gene expression analysis of DND41
shRNA control and PTEN shRNA knockdown cells treated
with dexamethasone. In agreement with a global inhibition of
glucocorticoid receptor activity by AKT, microarray analysis of
gene expression changes induced by dexamethasone treatment
showed complete abrogation of glucocorticoid-induced sig-
natures upon activation of AKT1 via PTEN shRNA knockdown
(Figure 3D). Moreover, gene set enrichment analysis (GSEA)
of genes regulated by glucocorticoids in primary leukemia
samples (Schmidt et al., 2006) showed a marked enrichment in
DND41 control cells treated with dexamethasone compared
with dexamethasone-treated PTEN shRNA knockdown samples
(Figure 3E).
Pharmacologic Inhibition of AKT Reverses
Glucocorticoid Resistance In Vitro and In Vivo
To test the therapeutic role of AKT inhibition in the treatment of
glucocorticoid-resistant leukemias, we first treated CCRF-CEM
cells, a PTEN null glucocorticoid-resistant T-ALL cell line, with
dexamethasone and MK2206. In these experiments, AKT1 inhi-
bition of CCRF-CEM lymphoblasts with MK2206 effectively
restored glucocorticoid-induced apoptosis and reversed gluco-
corticoid resistance in vitro (Figure 4A). Similar results were
obtained in the glucocorticoid-resistant MOLT3 and PF382
T-ALL cell lines (Figure S4A). Analysis of an extended panel of
cell lines including B precursor ALL (Figure S4B), diffuse large
B cell lymphoma (Figure S4C), and multiple myeloma (Fig-
ure S4D) lines showed additive effects with this combination,
suggesting that the synergistic interaction between glucocorti-
coids and AKT inhibition may be most prominently relevant in
the context of T-ALL.
Next, we analyzed the effects of MK2206 and glucocorticoid
in vivo in a xenograft model of glucocorticoid-resistant T-ALL.
CCRF-CEM cells expressing the luciferase gene were injected
intravenously in immunodeficient NOGmice, and tumor engraft-
ment was assessed by in vivo bioimaging at day 18. Animals
harboring homogeneous tumor burdens were treated with
vehicle only (DMSO), MK2206, dexamethasone, or MK2206
plus dexamethasone for 3 days. In this experiment, animals
treated with dexamethasone or MK2206 showed progressive
tumor growth similar to that observed in vehicle-treated controls,
while mice treated with MK2206 plus dexamethasone had(E) GSEA of genes regulated by glucocorticoids in ALL patients undergoing
glucocorticoid therapy in DND41 shRNA LUC dexamethasone-treated cells
compared with DND41 shRNA PTEN dexamethasone-treated cells. Data in
(A) and (C) are represented as mean ± SD.
See also Figure S3.
I
P
I
P
I
P
I
P
C
PI-
91.8
PI+ 
7.8
DMSO
TO+, PI-
73.20
TO-, PI+ 
25.02
PI-
7 .2
PI+ 
25.0
Dexa
PI-
PI+ 
21.4
MK2206
PI-
29.0
PI+ 
64.8
MK2206 
Dexa+
D
56
A
4.1
1.9093.7
6.1
4.189.41
5.7
2.192.1 18.5
0
20
40
60
80
100
A
po
pt
os
is
 (%
)
0
20
40
60
80
100
Vi
ab
ili
ty
 (%
)
Dexa
Annexin V
D
A
A-7
Annexin V
D
A
A-7
Annexin V
D
A
A-7
Annexin V
D
A
A-7
DMSO Dexa MK2206 MK2206 
Dexa+
DMSO
Dexa
MK2206
Dexa+
MK2206
p=0.004
n.s
p<0.001
p<0.001 p<0.001p<0.001
p<0.001p<0.001
MK2206DMSO
Dexa Dexa+MK2206
0
20
40
60
  80
100
Dexa
T-
A
LL
 #
19
 
ce
ll 
vi
ab
ili
ty
(%
)
p<0.001 p<0.001
p<0.001
p<0.001
0
20
40
60
  80
100
Dexa
T-
A
LL
 #
9 
ce
ll 
vi
ab
ili
ty
(%
)
p<0.001
p<0.001
p<0.001
p<0.001
0
10
20
30
40
  50
  60
T-
A
LL
 #
6 
ce
ll 
vi
ab
ili
ty
(%
)
Dexa
p=0.02
p<0.002
p<0.001
p<0.001
0
20
40
60
  80
100
Dexa
T-
A
LL
 #
37
 
ce
ll 
vi
ab
ili
ty
(%
)
p<0.001
p<0.001
p<0.001
p<0.001
0
20
40
60
  80
100
Dexa
T-
A
LL
 #
39
 c
el
l v
ia
bi
lit
y(
%
)
p<0.001
p<0.001
p<0.001
p<0.001
0
20
40
60
  80
100
Dexa
T-
A
LL
 #
28
 c
el
l v
ia
bi
lit
y(
%
)
p<0.001
p=0.002
p=0.01
p=0.006
0
20
40
   60
  80
T-
A
LL
 #
10
 
ce
ll 
vi
ab
ili
ty
(%
)
Dexa
p<0.001 p<0.001
p<0.001p=0.001
B
Ve
hic
le
De
xa
MK
22
06
De
xa
 +
MK
22
06
1.0
0.8
0.6
0.4
0.2
0
8
6
4
2
P
ho
to
n 
flu
x 
x1
08
0
5
10
15
20
25
Lu
ci
fe
ra
se
 a
ct
iv
ity
   
   
(x
10
6  
ce
lls
)
0
20
40
60
80
100
120
%
 le
uk
em
ia
 c
el
ls
(r
el
at
iv
e 
to
 c
on
tro
l)
Vehicle
Dexa
MK2206
Dexa+
MK2206P
ho
to
n 
flu
x 
x 
10
6
p<0.031
p<0.011
p<0.045
p<0.001
p<0.001
p<0.001
p<0.001
p=0.006
p=0.018
Day 0 +3 0 +3 0 +3 0 +3
24.9
56
77.1
Figure 4. Pharmacologic Inhibition of
AKT with MK2206 Reverses Glucocorticoid
Resistance
(A) Representative plots of apoptosis and cell
viability quantification in CCRF-CEM T-ALL cells
treated with vehicle only, MK2206 (100 nM),
dexamethasone (Dexa; 1 mM), or dexamethasone
plus MK2206 (Dexa + MK2206; 1 mM and 100 nM,
respectively) in combination in vitro.
(B) Tumor load quantification in vivo by biolumi-
nescence imaging and analysis of luciferase
activity and human CD45-expressing cells in the
bone marrow of CCRF-CEM T-ALL xenografts
treated with vehicle only, MK2206 (10 mg kg1
via oral gavage twice a day), dexamethasone
(5 mg kg1 via intraperitoneal injection), or
MK2206 (10 mg kg1 twice a day) plus dexa-
methasone (5 mg kg1).
(C and D) Representative plots (C) and quantifi-
cation (D) of cell viability in primograft T-ALL
samples treated with vehicle only, MK2206
(100 nM–10 mM), dexamethasone (10 nM–1 mM)
alone, and dexamethasone (10 nM–1 mM) plus
MK2206 (100 nM–10 mM) in combination.
Percentages of viable (PI), and nonviable
(PI+) cells are indicated. Bar graphs represent
mean ± SD.
See also Figures S1 and S4.
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AKT Inhibition Reverses Glucocorticoid Resistancesignificant antitumor responses (Figure 4B). Following these
results, we evaluated the response to the combination treatment
MK2206 plus dexamethasone in primary T-ALL lymphoblasts.
Toward this goal, we established viable in vitro cultures of
T-ALL leukemia primograft samples supported by bone marrow
MS5 stroma cells expressing the Delta-like 1 NOTCH1 ligand
(Armstrong et al., 2009). Treatment of T-ALL leukemia cultures
with MK2206 plus dexamethasone in combination showed
significantly increased antileukemic effects compared with
treatment with dexamethasone or MK2206 alone (Figures 4C,
4D, and S4E). Notably, the antileukemic effects of MK2206
plus dexamethasone were prominent in tumor samples with
PTEN loss (TALL#6, TALL#9, and T-ALL#28) but were also real-
ized in PTEN-expressing tumors with moderate levels of AKT1
activation (T-ALL #19, TALL#37, and T-ALL#39) (Figure S4F).Cancer Cell 24, 766–776,To further test the efficacy of this
treatment combination in vivo, we estab-
lished leukemia xenografts in NOD rag
gamma immunodeficient mice using
three independent glucocorticoid-resis-
tant primograft T-ALL samples infected
with lentiviruses expressing the luciferase
gene. Animals harboring homogeneous
tumor burdens by in vivo bioimaging
were treated with vehicle only (DMSO),
MK2206, dexamethasone, or MK2206
plus dexamethasone. In this experiment,
mice treated with dexamethasone
or MK2206 showed progressive tumor
growth similar to that observed in vehicle-
treated controls, while mice treated withMK2206 plus dexamethasone showed significant antitumor
responses (Figure 5). In these experiments, analysis of
AKT1 phosphorylation showed effective suppression of AKT1
signaling in mice treated with MK2206 and MK2206 plus
dexamethasone in vivo (Figures S5A and S5B). Moreover,
expression analysis of the TSC22D3 (GILZ) glucocorticoid re-
ceptor target (Ayroldi et al., 2007; D’Adamio et al., 1997; Riccardi
et al., 1999) and PARP-1 cleavage showed increased glucocor-
ticoid response and enhanced apoptosis in leukemia-infiltrated
tissues of mice treated with MK2206 plus dexamethasone in
combination, respectively (Figure S5A). Pharmacokinetic ana-
lysis of MK2206 and dexamethasone ruled out that this effect
could be mediated by decreased clearance of dexamethasone,
as the pharmacokinetic profile of this glucocorticoid was iden-
tical in animals treated with dexamethasone alone and miceDecember 9, 2013 ª2013 Elsevier Inc. 771
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Figure 5. Pharmacologic Inhibition of AKT Reverses Glucocorticoid Resistance in Primary Human T-ALL Xenografts In Vivo
(A–C) Representative examples of tumor load analysis via in vivo bioluminescence imaging in mice xenografted with three independent human T-ALLs treated
with vehicle only, MK2206 (10 mg kg1 twice a day), dexamethasone (5 mg kg1), or MK2206 (10 mg kg1 twice a day) plus dexamethasone (5 mg kg1).
(D–F) Quantitative analysis of tumor load and therapy response based on luciferase activity.
(G–I) Representative images of spleens in primary T-ALL xenografted mice at the end of treatment.
(J–L) Quantitative analysis of tumor burden estimated by spleen weight in T-ALL xenografted mice at the end of treatment. (M–O) Quantitative analysis of tumor
burden estimated by luciferase counts in bone marrow in T-ALL xenografted mice at the end of treatment. Bar graphs represent mean ± SD.
(A), (D), (G), (J), and (M) correspond to T-ALL #27. (B), (E), (H), (K), and (N) correspond to T-ALL #19. (C), (F), (I), (L), and (O) correspond to T-ALL #9. Scale bars,
2 cm. See also Figure S5.
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Figure 6. Pharmacologic Inhibition of AKT
Reverses Glucocorticoid Resistance in
a Mouse Model of Glucorticoid-Resistant
T-ALL
(A) Kaplan-Meier curve in mice treated with
dexamethasone (Dexa) or vehicle (Control)
after allograft transplantation of Pten-nondeleted
(Ptenf/f) NOTCH1-induced T-ALL tumor cells.
Arrows indicate drug treatment.
(B) Kaplan-Meier curve in mice treated with
dexamethasone (Dexa) or vehicle (Control) after
allograft transplantation of Pten-deleted (Pten/)
NOTCH1-induced T-ALL tumor cells. Arrows
indicate drug treatment.
(C and D) Representative images and changes
in bioluminescence by in vivo imaging (C), and
statistical analysis of differences in treatment
response (D) in mice allografted with NOTCH1-
induced Pten/ mouse leukemia cells treated
with vehicle only, MK2206 (10 mg kg1 via oral
gavage twice a day), dexamethasone (Dexa;
5 mg kg1), or MK2206 (10 mg kg1 twice a day)
plus dexamethasone (5 mg kg1) (Dexa +
MK2206).
(E) Kaplan-Meier overall survival curve in mice
allografted with NOTCH1-induced Pten/ mouse
leukemia cells and treated with vehicle only
(control), MK2206 (10 mg kg1 via oral gavage
twice a day), dexamethasone (Dexa; 5mg kg1), or
MK2206 (10 mg kg1 twice a day), plus dexa-
methasone (5 mg kg1) (Dexa + MK2206).
(F and G) Quantification of glucocorticoid-induced
loss of viability in isogenic NOTCH1-induced
Ptenf/f or Pten/ mouse leukemia cells infected
with retroviruses expressing the wild-type (F) or
the S134A mutant (G) glucocorticoid receptor
NR3C1. Data are represented as mean ± SD.
See also Figure S6.
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AKT Inhibition Reverses Glucocorticoid Resistancetreated with MK2206 plus dexamethasone in combination (Fig-
ure S5C). In addition, even though we observed a modest
decrease in MK2206 half life in mice treated with dexametha-
sone plus MK2206 (Figure S5C), AKT inhibitor levels obtained
in animals treated with MK2206 as single agent already result
in complete suppression of AKT activation in vivo (Figures S5A
and S5B), supporting the conclusion that this pharmacokinetic
interaction does not account for the increased antileukemic
responses observed in mice treated with dexamethasone plus
MK2206.
Finally, we generated a mouse leukemia model in which
glucocorticoid resistance is specifically driven by genetic loss
of Pten using a well-established retroviral transduction and
bone marrow transplantation protocol (Chiang et al., 2008). InCancer Cell 24, 766–776,this model, transplantation of tamox-
ifen-inducible conditional Pten knockout
(ROSA26Cre-ERT2/+;Ptenf/f) hematopoietic
progenitors infected with retroviruses
expressing a mutant constitutively
active form of the NOTCH1 receptor
(NOTCH1 L1601P DPEST) resulted in
the development of NOTCH1-driven
T-ALL tumors as described elsewhere(Chiang et al., 2008). Next, we infected NOTCH1 L1601P
DPEST, ROSA26Cre-ERT2/+, Ptenf/f T-ALL lymphoblasts with a
luciferase-expressing retrovirus and transplanted them into
secondary recipients that were treated with vehicle only or
tamoxifen in order to generate Pten-nondeleted and Pten-
deleted isogenic tumors, respectively. Treatment of Pten-non-
deleted tumor-bearing mice with dexamethasone showed a
significant improvement in survival compared with controls
treated with vehicle only (Figure 6A). In contrast, and consis-
tent with a role of Pten loss and AKT1 activation in promoting
glucocorticoid resistance, all mice harboring Pten-deleted
tumors failed to respond to dexamethasone treatment and
showed no survival differences compared to vehicle-treated
controls (Figure 6B).December 9, 2013 ª2013 Elsevier Inc. 773
Cancer Cell
AKT Inhibition Reverses Glucocorticoid ResistanceTo test the efficacy of MK2206 and glucocorticoids in combi-
nation, we treated mice transplanted with NOTCH1-induced
Pten-deleted murine tumors expressing luciferase in secondary
recipients, with vehicle only (DMSO), MK2206, dexamethasone,
or MK2206 plus dexamethasone and monitored their response
to therapy by in vivo bioimaging. Animals treated with dexa-
methasone or MK2206 in this experiment showed progressive
tumor growth similar to that observed in vehicle-treated con-
trols, while mice treated with MK2206 plus dexamethasone
showed significant antitumor responses (Figures 6C and 6D),
which translated in significantly improved survival in this
group (Figure 6E). As before, analysis of AKT1 phosphorylation
showed effective suppression of AKT1 signaling in mice
treated with MK2206 and MK2206 plus dexamethasone
in vivo (Figure S6A), while GILZ expression analysis showed
increased glucocorticoid response (Figure S6A) and PARP-1
cleavage demonstrated increased apoptosis in tumor cells
from animals treated with MK2206 plus dexamethasone in
combination (Figure S6A). Consistently, histological analysis
of leukemia-infiltrated bone marrow showed increased antileu-
kemic effects (Figure S6B) and marked increased apoptosis
(Figure S6C) in mice xenografted with NOTCH1-induced
Pten/ T-ALL cells treated with MK2206 plus dexamethasone
in combination.
Finally, we analyzed the role of NR3C1 S134 phosphorylation
in the therapeutic response to glucocorticoids and the effects
of Pten loss in glucocorticoid therapy in this model. Retroviral
expression of the glucocorticoid receptor enhanced the
response of NOTCH1-induced Pten nondeleted leukemias
to glucocorticoid treatment, an effect that was effectively
abrogated upon Pten loss (Figures 6F and S6D). In contrast,
expression of the AKT-resistant NR3C1 S134A mutant protein
was equally effective at increasing the antileukemic effects of
glucocorticoids in Pten nondeleted and Pten null lymphoblasts
(Figures 6G and S6D). Overall, these results support that
pharmacologic inhibition of AKT can effectively enhance
glucocorticoid response and reverse glucocorticoid resistance
in T-ALL.
DISCUSSION
Numerous mechanisms have been proposed to explain the lack
of effective glucocorticoid-induced apoptosis in prednisone
poor responders (Bhadri et al., 2012). However, and despite
much research over the last 2 decades, the molecular basis
of primary glucocorticoid resistance in ALL remains poorly
understood. Given that primary glucocorticoid resistance is a
cell-intrinsic property of leukemia lymphoblasts present before
exposure to glucocorticoid therapy, we proposed that primary
oncogenic signaling pathways involved in leukemia transforma-
tion could also function as negative upstream regulators of the
glucocorticoid receptor driving this phenotype. The identification
of AKT1 as a driver of glucocorticoid resistance in T-ALL is
perfectly consistent with this model. Notably, direct activation
of AKT1 can drive T cell transformation (Kharas et al., 2010),
activation of PI3K-AKT signaling as a result of deletions and
mutations in PTEN (Palomero et al., 2007) is highly prevalent
in T-ALL, and PTEN mutations are associated with primary
glucocorticoid resistance in the clinic (Bandapalli et al., 2013).774 Cancer Cell 24, 766–776, December 9, 2013 ª2013 Elsevier Inc.Mechanistically, we show that AKT1 can induce glucocorti-
coid resistance by phosphorylation of the glucocorticoid recep-
tor in position S134, which impairs the nuclear relocalization of
the glucocorticoid receptor protein and blocks transcriptional
regulation of glucocorticoid target genes. However, it should
be noted that additional mechanisms downstream of AKT1 in
addition to direct inactivation of the glucocorticoid receptor
can also promote resistance to glucocorticoid therapy by
promoting cell growth, metabolism, and survival in T-ALL. In
this regard, mTOR phosphorylation by AKT impairs glucocorti-
coid-induced apoptosis by increasing the expression of MCL1
(Wei et al., 2006). In addition, AKT phosphorylation inhibits
BAD-mediated apoptosis (Bornhauser et al., 2007; Datta
et al., 1997; del Peso et al., 1997); AKT-mediated phosphoryla-
tion of XIAP prevents the autoubiquitination and subsequent
degradation of this antiapoptotic factor (Bornhauser et al.,
2007; Dan et al., 2004); and increased metabolism induced
by AKT activation can antagonize metabolic inhibition induced
by glucocorticoids (Beesley et al., 2009). The convergent ef-
fects of direct and indirect mechanisms downstream of AKT1
antagonizing the antileukemic effects of glucocorticoids further
support the role of the PI3K-AKT pathway as therapeutic target
for the reversal of primary glucocorticoid resistance in T-ALL.EXPERIMENTAL PROCEDURES
Patient Samples
T-ALL samples were provided by Columbia Presbyterian Hospital, the Eastern
Cooperative Oncology Group (ECOG), University of Padova, and Hospital
Central de Asturias with informed consent and analyzed under the supervision
of the Columbia University Medical Center Institutional Review Board
committee.
Inhibitors and Drugs
MK2206 or 8-[4-(1-aminocyclobutyl)phenyl]-9-phenyl-1,2,4-triazolo[3,4-f]
[1,6]naphthyridin-3 (2H)-one hydrochloride [1:1] was from Selleck Chemicals
LLC. Dexamethasone and 4-Hydroxytamoxifen were from Sigma-Aldrich.
In Vitro Kinase Assays
Flag-tagged recombinant GST-NR3C1 and GST-NR3C1 S134A mutant
proteins were incubated with recombinant active His-AKT1 protein (Millipore)
in kinase buffer (Cell Signaling) containing g-32P-ATP and analyzed by autora-
diography after SDS-PAGE.
Mass Spectrometry
HA-NR3C1 protein was immunoprecipitated from U2OS cells stably express-
ing HA-tagged human NR3C1 andMyr-AKT with anti-HA antibody-conjugated
beads (Sigma), electrophoresed on a 3%–8% Tris-acetate gel, stained with
Simply Blue Stain (Invitrogen), excised, reduced with dithiothreitol, alkylated
with iodoacetamide, digested with trypsin, and analyzed for phosphorylated
peptides by nanoscale liquid chromatographic tandem mass spectrometry
(LC-MS/MS). MS/MS spectra were processed using ProteinLynx from the
MassLynx 4.0 software and searched against the Swiss-Prot protein database
using Mascot (http://www.matrixscience.com) with differential modifications
for Ser/Thr/Tyr phosphorylation (+79.97).
To test the effects of AKT1 inhibition on NR3C1 S134 phosphorylation, we
treated U2OS cells stably expressing HA-tagged human NR3C1 and the
constitutively active Myr-AKT with DMSO or MK2206 (10 mM, 5 hr). We
immunoprecipitated HA-NR3C1 protein with anti-HA antibody-conjugated
beads (Sigma). Immunopurified HA-NR3C1 was then electrophoresed on a
4%–12% Bis-Tris gel, stained with Simply Blue Stain (Invitrogen), digested
with trypsin, and analyzed for the phosphorylation status at residue S134 by
microcapillary LC-MS/MS.
Cancer Cell
AKT Inhibition Reverses Glucocorticoid ResistanceImmunofluorescence
We analyzed U2OS cells stably expressing wild-type NR3C1 or the S134A
NR3C1 by NR3C1 immunofluorescence (1:500; Santa Cruz Biotechnology),
followed by Alexa Fluor 594 (1:1,000; Invitrogen) staining and confocal micro-
scopy. In colocalization studies, T-ALL cell lines were immunostained with
rabbit antibodies against NR3C1 (1:300; Santa Cruz Biotechnology) and a
mouse antibody against AKT (1:100) (Cell Signaling, #2920) using anti-rabbit
Alexa Fluor 594 (1:500; Invitrogen) and anti-mouse Alexa Fluor 488 (1:500;
Invitrogen) as secondary antibodies. We stained nuclei with TO-PRO3 reagent
(Invitrogen) and visualized them by confocal imaging on a Zeiss LSM510-NLO
microscope.
Luciferase Reporter Assays
We performed NR3C1 reporter assays using the Cignal GRE Reporter (luc)
Kit (SABiosciences).
Microarray Expression Analysis of Glucocorticoid Response
DND41 shRNA LUC and DND41 PTEN shRNA cells were treated with vehicle
only (DMSO) or dexamethasone (1 mM) for 24 hr in triplicate. RNA was iso-
lated, labeled, and hybridized to the HumanHT-12 v4 Expression BeadChip
(Illumina) using standard procedures. Raw gene expression data were log
transformed and quantile normalized using MATLAB. Differentially regulated
genes in DND41 shRNA LUC versus DND41 PTEN shRNA upon dexameth-
asone treatment with a fold change >2 were selected by t test. Glucocorti-
coid-regulated transcripts (t test, p < 0.01, and fold change >1.25) in primary
ALL were identified from processed expression data obtained from
peripheral blood lymphoblasts from 13 pediatric ALL patients after 24 hr
of treatment with glucocorticoids (Schmidt et al., 2006). Enrichment of
these glucocorticoid signature genes in shRNA PTEN versus shRNA
LUC dexamethasone-treated samples normalized to DMSO controls was
analyzed by GSEA using the t test metric and 1,000 permutations of the
genes.
Mice
Animal procedures were approved by the Columbia University Institutional
Animal Care and Use Committee. ROSA26Cre-ERT2/+mice expressing a tamox-
ifen-inducible form of the Cre recombinase from the ubiquitous Rosa26
locus (Guo et al., 2007) and Pten conditional knockout mice (Ptenf) have
been described elsewhere (Trotman et al., 2003). To generate NOTCH1-
induced T-ALL tumors in mice, we performed retroviral transduction of
bone marrow cells with an activated form of the NOTCH1 oncogene
(NOTCH1 L1601P DPEST) and transplanted them via intravenous injection
into lethally irradiated recipients as described elsewhere (Chiang et al.,
2008). Primary human T-ALL xenografts experiments were generated via
intravenous injection of human T-ALL lymphoblasts into NOD rag gamma
mice. We evaluated disease progression and therapy response by in vivo
bioimaging with the In Vivo Imaging System (Xenogen), human CD45 analysis
by flow cytometry, and analysis of luciferase activity in bone marrow and
spleen.
Statistical Analyses
We performed statistical analysis using Student’s t test and Wilcoxon signed-
rank test. We considered results with p < 0.05 as statistically significant.
Survival in animal experiments was represented with Kaplan-Meier curves,
and significance was estimated with the log-rank test (Prism GraphPad).
ACCESSION NUMBERS
Microarray gene expression data are available in Gene Expression Omnibus
under accession numbers GSE41062 and GSE32215.
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